These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 8434357)

  • 1. Aerosolised ribavirin in patients with advanced cryptogenic fibrosing alveolitis: a pilot study.
    Agustí C; Xaubet A; Ballester E; Alarcón A; Picado C
    Thorax; 1993 Jan; 48(1):68-9. PubMed ID: 8434357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional similarities of asbestosis and cryptogenic fibrosing alveolitis.
    Markos J; Musk AW; Finucane KE
    Thorax; 1988 Sep; 43(9):708-14. PubMed ID: 3194877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose intravenous methylprednisolone pulse therapy as initial treatment in cryptogenic fibrosing alveolitis. A pilot study.
    Gulsvik A; Kjelsberg F; Bergmann A; Frøland SS; Rootwelt K; Vale JR
    Respiration; 1986; 50(4):252-7. PubMed ID: 3823635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epstein-Barr virus replication within pulmonary epithelial cells in cryptogenic fibrosing alveolitis.
    Egan JJ; Stewart JP; Hasleton PS; Arrand JR; Carroll KB; Woodcock AA
    Thorax; 1995 Dec; 50(12):1234-9. PubMed ID: 8553293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Asbestosis and cryptogenic fibrosing alveolitis: a radiological and functional comparison.
    Cookson WO; Musk AW; Glancy JJ
    Aust N Z J Med; 1984 Oct; 14(5):626-30. PubMed ID: 6597709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutrophil activation in fibrosing alveolitis: a comparison of lone cryptogenic fibrosing alveolitis and systemic sclerosis.
    Cailes JB; O'Connor C; Pantelidis P; Southcott AM; Fitzgerald MX; Black CM; du Bois RM
    Eur Respir J; 1996 May; 9(5):992-9. PubMed ID: 8793462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating antibodies to lung protein(s) in patients with cryptogenic fibrosing alveolitis.
    Wallace WA; Roberts SN; Caldwell H; Thornton E; Greening AP; Lamb D; Howie SE
    Thorax; 1994 Mar; 49(3):218-24. PubMed ID: 8202877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival in patients with cryptogenic fibrosing alveolitis: a population-based cohort study.
    Hubbard R; Johnston I; Britton J
    Chest; 1998 Feb; 113(2):396-400. PubMed ID: 9498958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High resolution computed tomographic assessment of asbestosis and cryptogenic fibrosing alveolitis: a comparative study.
    al-Jarad N; Strickland B; Pearson MC; Rubens MB; Rudd RM
    Thorax; 1992 Aug; 47(8):645-50. PubMed ID: 1412123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The predictive value of appearances on thin-section computed tomography in fibrosing alveolitis.
    Wells AU; Hansell DM; Rubens MB; Cullinan P; Black CM; du Bois RM
    Am Rev Respir Dis; 1993 Oct; 148(4 Pt 1):1076-82. PubMed ID: 8214928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exposure to commonly prescribed drugs and the etiology of cryptogenic fibrosing alveolitis: a case-control study.
    Hubbard R; Venn A; Smith C; Cooper M; Johnston I; Britton J
    Am J Respir Crit Care Med; 1998 Mar; 157(3 Pt 1):743-7. PubMed ID: 9517585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cryptogenic fibrosing alveolitis. Clinical spectrum and treatment.
    Louw SJ; Bateman ED; Benatar SR
    S Afr Med J; 1984 Feb; 65(6):195-200. PubMed ID: 6695282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study.
    Hubbard R; Venn A; Lewis S; Britton J
    Am J Respir Crit Care Med; 2000 Jan; 161(1):5-8. PubMed ID: 10619790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional impairment in lone cryptogenic fibrosing alveolitis and fibrosing alveolitis associated with systemic sclerosis: a comparison.
    Wells AU; Hansell DM; Rubens MB; Cailes JB; Black CM; du Bois RM
    Am J Respir Crit Care Med; 1997 May; 155(5):1657-64. PubMed ID: 9154872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rising mortality from cryptogenic fibrosing alveolitis.
    Johnston I; Britton J; Kinnear W; Logan R
    BMJ; 1990 Nov; 301(6759):1017-21. PubMed ID: 2249048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accuracy of diagnostic coding of hospital admissions for cryptogenic fibrosing alveolitis.
    Johnston ID; Bleasdale C; Hind CR; Woodcock AA
    Thorax; 1991 Aug; 46(8):589-91. PubMed ID: 1926030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spontaneous pneumothorax in cryptogenic fibrosing alveolitis.
    Picado C; Gómez de Almeida R; Xaubet A; Montserrat J; Letang E; Sánchez-Lloret J
    Respiration; 1985; 48(1):77-80. PubMed ID: 4023442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. British Thoracic Society study of cryptogenic fibrosing alveolitis: current presentation and initial management. Fibrosing Alveolitis Subcommittee of the Research Committee of the British Thoracic Society.
    Johnston ID; Prescott RJ; Chalmers JC; Rudd RM
    Thorax; 1997 Jan; 52(1):38-44. PubMed ID: 9039238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clearance of inhaled 99mTc-DTPA predicts the clinical course of fibrosing alveolitis.
    Wells AU; Hansell DM; Harrison NK; Lawrence R; Black CM; du Bois RM
    Eur Respir J; 1993 Jun; 6(6):797-802. PubMed ID: 8339797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lone cryptogenic fibrosing alveolitis: a functional-morphologic correlation based on extent of disease on thin-section computed tomography.
    Wells AU; King AD; Rubens MB; Cramer D; du Bois RM; Hansell DM
    Am J Respir Crit Care Med; 1997 Apr; 155(4):1367-75. PubMed ID: 9105081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.